Life Insurance Corporation of India Leadership Appointment in Senior Management

Life Insurance Corporation of India (LIC) has announced the appointment of Mr. Pankaj Kumar Saxena as the new Executive Director (Alternate Channel) at its Central Office. Effective April 10, 2026, this leadership change follows his successful tenure as the Managing Director & Chief Executive Officer of LIC Pension Fund Limited, bringing over 35 years of deep industry expertise to his new role within the Corporation.

Leadership Transition

Life Insurance Corporation of India has officially designated Mr. Pankaj Kumar Saxena as a member of its Senior Management Personnel. As of April 10, 2026, Mr. Saxena assumes the role of Executive Director (Alternate Channel) at the Central Office, transitioning from his previous leadership position at LIC Pension Fund Limited.

Professional Background and Expertise

Mr. Saxena brings a wealth of experience to his new position, having joined the Corporation in 1990 as an Assistant Administrative Officer. Throughout his career spanning more than 35 years, he has held diverse administrative and marketing roles across various regions, including the North Central, Northern, and Central Zones.

His extensive background includes a 27-year tenure focused specifically on marketing operations. During this period, he served in several key leadership capacities, such as Manager (Sales), Chief Manager, and Senior Divisional Manager for the Allahabad and Dehradun divisions. He also previously held the position of Regional Manager (Marketing) for the North Central Zone in Kanpur before leading the LIC Pension Fund Limited as its MD & CEO.

Educational Qualifications

Mr. Saxena holds a post-graduate degree in Mathematics, complemented by a Post Graduate Diploma in Marketing Management. His deep institutional knowledge and leadership history are expected to contribute significantly to the strategic objectives of the Alternate Channel division at the Corporation.

Source: BSE

Previous Article

Embassy Developments Limited Strong FY26 Performance Amidst Legal Updates

Next Article

AstraZeneca Pharma India New Indication Approved for Calquence